Oct 21,2021

DarioHealth unveils digital therapy for treating musculoskeletal conditions

DarioHealth (NSDQ:DRIO) announced that it launched Dario Move, a digital physical therapy platform for musculoskeletal (MSK) conditions. Dario Move combines software, technology and professional human support with features including a single biofeedback sensor for ease of use, personalized evidence-based exercise programs designed by physical therapists, real-time feedback and support and a highly personalized experience across Dario’s full suite of chronic condition solutions.

PRODUCT

#software

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 25,2021

DarioHealth Announces Contract with a U.S. National Employer to Provide Its Full Multi-Condition Suite Digital Therapeutic Solutions

DarioHealth announced today that it has entered into a contract with a U.S. national employer (the "Employer") for the Company's full multi-condition suite of chronic condition management solutions, including diabetes, pre-diabetes, hypertension, musculoskeletal, behavioral health, and digital employee assistance programs. Enrollment of the Company's multi-condition suite of chronic condition management solutions is expected to begin in the first quarter of 2022, consistent with the Employer's benefit year.

PRODUCT

#coaching

#software

View Analyst & Ambassador Comments
Go to original news
Oct 27,2021

DarioHealth joins Virgin Pulse partner network

DarioHealth today announced it has partnered with Virgin Pulse, the leading global provider of digital and live health and wellbeing solutions, making its next-gen digital therapeutic and health solutions available for contract through Virgin Pulse to employers and health plans worldwide. The company's preconfigured benefits will be available to eligible employees and health plan members through Virgin Pulse's Homebase for Health® solution.

COLLABORATION PARTNERSHIP

#institution

#software

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 01,2021

DarioHealth Gathers Momentum in the Provider Market with Two New Contracts for Remote Patient Monitoring Services

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into contracts with two prominent regional providers in Hawaii and Georgia for its Remote Patient Monitoring (RPM) services. Both partnerships will provide RPM services for patients living with diabetes and hypertension, two of the most common – and commonly co-occurring - chronic conditions.

PRODUCT

#rpm

#software

View Analyst & Ambassador Comments
Go to original news
Dec 01,2021

Happify Health Selects Copado To Accelerate Delivery Of Its Clinical-Grade Intelligent Healing Platform

Copado, a leading DevOps platform, and Happify Health, a software platform for improving mental and physical health, announced a partnership to accelerate the global distribution of Happify Health’s Intelligent Healing Platform. Copado is providing software and services to enhance the scalability of Happify’s platform by enabling advanced data interoperability, payer-to-payer data exchange, and multi-cloud and consent governance capabilities, which will accelerate Happify’s time-to-market and expand Happify’s market opportunity within the Salesforce, Microsoft and Veeva ecosystems.

COLLABORATION PARTNERSHIP

#product & service

#software

View Analyst & Ambassador Comments
Go to original news
Dec 16,2021

Pear Therapeutics Announces The Acquisition Of Two Assets Addressing A Comprehensive Spectrum Of Depression Conditions

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the continued development of its PDT product candidate pipeline. Pear acquired and/or licensed two new digital therapeutic assets, from Waypoint Health Innovations, LLC and a researcher named Fredrik Holländare of Örebro University, that are designed for the treatment of a spectrum of depression conditions. Pear intends to leverage these two new assets to expand its depression product candidate to treat mild, moderate, severe, and treatment-refractory depression.

PRODUCT

#cbt

#software

View Analyst & Ambassador Comments
Go to original news
Jan 14,2021

Amalgam Rx Acquires Clinical Decision Support Platform Avhana Health – M&A

Amalgam Rx, Inc., a Wilmington, DE-based Digital Therapeutics and Patient Support company, announces the acquisition of Avhana Health, a privately held clinical decision support (CDS) company, which has deep integrations with the leading electronic health records (EHR). As part of the acquisition, Amalgam Rx will expand Avhana’s CDS tools to multiple therapeutic areas and combine them with other digital solutions to simplify doctors’ workflows.

COLLABORATION MERGERS & ACQUISITION

#product & service

#software

View Analyst & Ambassador Comments
Go to original news
Feb 15,2021

Voluntis announces issuance of European patent for drug dosing support with its Theraxium digital therapeutic platform

Voluntis, a leader in digital therapeutics, announced today the issuance of a new patent by the European Patent Office (EPO) for intelligent patient support in drug dosing applied in the field of diabetes for insulin titration support. Following the prescription of the drug and its companion digital therapeutic, the intelligent and adaptive algorithms developed by Voluntis will automatically recommend to a patient, day by day and according to the evolution of their monitoring data, a progressive increase of the dose to bring the patient into the target range as specified by their physician. Safety mechanisms are also present to decrease the dose if the situation requires it. Once the target range is reached, the dose will then remain stable as long as the patient’s follow-up data stays within the target range.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Feb 18,2021

Psychedelic biotech MindMed scoops up research focused digital health company HealthMode

Psychedelic biotech company MindMed is set to acquire research focused digital health company HealthMode for roughly $32.2 million (CAD $41M). HealthMode works with researchers and institutions to help digitize studies by using an artificial intelligence-enabled platform that can capture patient data and synthesize information. According to its website, the company is able to model disease trajectories, predict prognoses and detect any clinical changes.

COLLABORATION MERGERS & ACQUISITION

#product & service

#software

View Analyst & Ambassador Comments
Go to original news
Subscribe to SOFTWARE